Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


NICE TA: 317
Indication: with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (NICE TA317)
Disease category: Cardiovascular
Commissioning responsibility: CCG
PbR excluded: No


This guidance replaces NICE technology appraisal guidance 182 issued in October 2009. Prasugrel (Efient®)10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention. The updated recommendations for prasugrel with percutaneous coronary intervention for treating acute coronary syndromes include people with high-risk NSTEMI and unstable angina who do not have diabetes mellitus.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG


Amber 0